• Search
  • Advanced Search
Clin Mol Hepatol > Accepted Articles
Editorial
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response
Hiroaki Kanzaki1,2, Yujin Hoshida2
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan
2Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, U.S.
Correspondence :  Yujin Hoshida ,
Email: Yujin.Hoshida@UTSouthwestern.edu
Received: August 28, 2024   Accepted: August 29, 2024
KeyWords: hepatocellular carcinoma; immunotherapy; predictive biomarker; molecular signatures
TOOLS
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 240 View
  • 18 Download
Related articles

Correspondence on Letter regarding “Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response.”

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma

Systemic therapy in advanced hepatocellular carcinoma2023 April;29(2)

Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease2022 October;28(4)

Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?2017 September;23(3)

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1149
TOTAL : 2092410
Close layer